Navigation Links
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
Date:9/3/2008

BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and Selexis SA announced today a new milestone in CHO based monoclonal antibody production with the achievement of manufacturing yields of over 31 grams per liter. This record level was accomplished by applying two highly innovative technologies: (1) a high-performance stable Selexis CHO production cell line rapidly generated by industry leading scientists at Selexis SA using their proprietary Selexis Genetic Elements(TM) and (2) the application of iCELLis(TM) scalable, disposable, high-cell-density technology developed by the innovative scientists at Artelis.

The full program was concluded over about 4 months, starting with the development of a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry standard cGMP grade and void of serum or any animal derived components.

Dr. Igor Fisch, Co-founder and CEO of Selexis commented on the achievements:

"The productivity and stability of the Selexis high-performance cell lines are a perfect fit for the iCELLis(TM) technology, which has the ability to reach incredibly high-cell-densities of up to 250 mio cells per ml". "The usefulness and potential applications of the combined approach could stretch across the biotech industry, beyond just large scale bioproduction".

Dr. Jose Castillo, Co-founder and President of Artelis commented on the achievements:

"These results show the power of the iCELLis(TM) technology. When combined with a high-performance cell line, like one from Selexis', we have the opportunity to reach ultra high productivity levels." "We firmly believe the iCELLis(TM) system will change the approach companies take for the small and large scale production of recombinant proteins."

Further details on this milestone achievement will be presented at the upcoming Bioprocess International Conference being held in Anaheim, California, September 23 -- 26, 2008.

Artelis and Selexis plan to expand the testing of the combined technologies by evaluating the iCELLis(TM) platform with Selexis generated HEK293 cells lines.

About the Artelis iCELLis(TM) Technology:

iCELLis (TM) is a proprietary, single-use, technology developed by Artelis. iCELLis(TM) is designed to achieve and maintain high-cell densities on macrocarriers in a fixed-bed system. Achieving high-cell densities allows compact iCELLis(TM) bioreactors to equal the productivity of much larger stirred-tank units. Depending on cell type and process, iCELLis(TM) can achieve 20-100x the volumetric productivity of a stirred-tank bioreactor.

iCELLis(TM) represents the next generation of disposable bioreactor technology, enabling process intensification in upstream processing by reducing bioreactor scale and simplifying operations.

About Artelis:

Artelis is an international and innovative SME founded in 2005. Capitalised by an American company listed on NASDAQ, Artelis is the privileged partner of world-leading pharmaceutical groups. The company has broad experience with disposable technologies: Artelis developed the Newmix(R) Jet Drive(TM), disposable mixing system, and co-developed the Nucleo(TM) disposable bioreactor together with ATMI Lifesciences and Pierre Guerin Biolafitte. Artelis is concerned by the process intensification needs in the biotech industry and dedicated to process development in disposable technologies. Artelis' mission is to create the future means of producing proteins, cells and viruses for key markets: monoclonal antibodies, cell therapy, vaccines and gene therapy. For more information, please visit http://www.artelis.be.

About the Selexis Genetic Elements(TM):

Selexis Genetic Elements (TM) are applied to control the dynamic organization of transgenes in the chromatin of eukaryotic production cells. The Selexis Genetic Elements(TM) enable the creation of loops of open chromatin upon the stable integration of the SGE containing vectors. Selexis Genetic Elements(TM) based vectors have been shown to significantly increase the population of independently transformed cells stably expressing the gene of interest at very high levels. Selexis Genetic Elements(TM) are available for out-license.

About Selexis SURE Cell Line Development(SM) Program: The Selexis SURE Cell Line Development(SM) program is a novel cell line development procedure designed to maximize the effectiveness of the Selexis technology. Using the Selexis SURE Cell Line Development program, Selexis scientists can generate high-performance stable minipools in as little as 5 week following transfection or high-performance clonal cell lines 12 weeks after transfection. Like the Selexis Genetic Elements(TM) the Selexis SURE Cell Line Development Program is available for out-license.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

For more information visit Selexis at http://www.selexis.com.

Selexis Genetic Elements(TM) and SURE Cell Line Development(SM) are trademarks of Selexis SA.

iCELLis(TM) is a trademark of Artelis SA.


'/>"/>
SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
2. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
3. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
4. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
7. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Newborns are highly vulnerable to infections ... their young immune systems typically mount weak antibody ... achieving strong vaccine responses in newborn animals, including ... trials — by adding compounds known as adjuvants ... papers, they also describe improved adjuvant formulations that ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
(Date:3/23/2017)... , March 23, 2017 ... Composite ended the trading session at 5,821.64, up ... lower, to finish at 20,661.30; and the S&P ... were broad based as six out of nine ... Stock-Callers.com has initiated reports coverage on the following ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):